Atlas Trials

A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

Clinical trial NCT00721045 · COMPLETED

Trial details

NCT number
NCT00721045
Sponsor
Mesoblast, Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Heart Failure
Start date
2008-08-01
Primary completion
2011-06-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.